Award-winning cosmetic surgery practice recognized for breast augmentation, tummy tuck, and body contouring excellenceOMAHA, ...

Revenue rose 38% from $1,169,622 to $1,609,473 in the second quarter of fiscal year 2024Revenue Increase was more than 11X Industry Growth RateExpanding Profit Margins: Gross Margins increased 53% ...

Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression Treatment MIAMI, FL / ACCESSWIRE / November 20, 2024 / ...

AI-equipped H3 Health Cube Displayed at the Annual Assembly of the National Association of Italian Municipalities VANCOUVER, BC / ACCESSWIRE / November 20, 2024 / UniDoc Health Corp.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Following the announcement, Richard Torbet, Chief Executive of the Association of the British Pharmaceutical Industry (ABPI), said: “I would like to offer my warm congratulations to Professor Harnden ...

Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands, and Sweden, announces the full Good Manufacturing ...

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord ...

Oxford-based SynaptixBio, which is developing an antisense oligonucleotide (ASO) to ‘silence’ the expression of a single mutated gene, says the ASO market is set to grow dramatically, largely because ...

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a ...

Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has secured £1 million in grant funding from ...